Truncated fragments of alpha-synuclein in Lewy body disease
US7358331B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2005 |
| Grant date | Apr 15, 2008 |
| Priority date | — |
| Expiry date | Mar 26, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2835
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.